Abiomed (NSDQ:ABMD) posted first-quarter results today that beat the consensus on Wall Street. The Danvers, Mass.-based company reported profits of $44.6 million, or 98¢ per share, on sales of $164.9 million for the three months ended June 30, for a bottom-line loss of -95% sales loss of -20.6% compared with Q1 2019. Adjusted to exclude one […]
FDA issues EUA for Abiomed Impella heart pumps for COVID-19 therapy
Abiomed (NSDQ:ABMD) announced today that the FDA issued emergency use authorization (EUA) for its Impella heart pumps in COVID-19 therapy. The EUA covers the left-sided Impella pumps in providing left ventricular unloading, supporting COVID-19 patients who are undergoing extracorporeal membrane oxygenation (ECMO) treatment and develop pulmonary edema or myocarditis, according to a news release. Impella, the […]
Abiomed touts results of U.S. study of its latest Impella heart pump
Abiomed (NSDQ:ABMD) says a study of U.S. patients receiving the new Impella 5.5 with SmartAssist found that 84% survived to explant and 76% experienced native heart recovery. The study — published in the July edition of the American Society for Artificial Internal Organs (ASAIO) Journal — examined the outcomes of the first 55 patients treated with Impella […]
Abiomed appoints new chief medical officer
Abiomed (NSDQ:ABMD) today said it appointed Charles Simonton as VP and chief medical officer. Simonton most recently served as chief medical officer and divisional VP of global medical affairs at Abbott Vascular where he led programs that resulted in FDA approval of carotid stents, MitraClip and Absorb BVS. He has also spent almost 30 years as […]
FDA approves Abiomed’s Impella ECP clinical trial
Abiomed (NSDQ:ABMD) announced today that it received FDA investigational device exemption approval to begin a clinical trial for the Impella ECP heart pump. Impella ECP (expendable cardiac power) will be studied in the early feasibility, first-in-human trial for high-risk percutaneous coronary intervention (PCI) patients, according to a news release. The prospective, multi-center, non-randomized trial will assess […]
FDA issues EUA for Abiomed Impella RP to treat COVID-19 heart failure
Abiomed (NSDQ:ABMD) announced that it received FDA emergency use authorization (EUA) for its Impella RP for use with COVID-19-related right heart failure. The Impella RP temporary heart pump provides circulatory support for patients with right side ventricular failure. It won FDA approval in September 2017 for such an indication and in October 2019 Abiomed reported real-world data […]
Abiomed stock up amid Street-beating Q4 profits, news of Breethe acquisition
Abiomed (NSDQ:ABMD) shares are up 10% in morning trading today after the company posted Street-beating Q1 results and announced the acquisition of Breethe and its potential coronavirus-fighting tech. The Danvers, Mass.-based maker of circulatory support devices — including Impella heart pumps — posted profits of $31.8 million, or 70¢ per share, on sales of $206.7 million […]
Judge tosses wrongful termination suit against Abiomed
Abiomed (NSDQ:ABMD) has convinced a federal judge that whistleblower Max Bennett had no basis on which to claim the company fired him in retaliation for his investigation of federal False Claims Act violations. Judge Indira Talwani ruled on Tuesday that “no reasonable jury could find that Bennett had engaged in protected activity or that he was […]
Abiomed beats on earnings, misses on revenue in Q3 results
Abiomed (NSDQ:ABMD) posted third-quarter results that beat the earnings consensus on Wall Street, but missed on revenue. The Danvers, Mass.-based company reported profits of $69.2 million, or $1.51 per share, on sales of $221.6 million for the three months ended Dec. 31, 2019, for a bottom-line gain of 54.3% sales growth of 10.5% compared with Q3 […]
Journal editors say study of Abiomed’s Impella pumps limited
This article has been updated with a comment from Abiomed. A medical journal editorial has cast doubt on the findings of a research study that sent shares in Abiomed (NSDQ:ABMD) down sharply in November. The editorial in the journal Circulation said the study’s methodology had several limitations and called for randomized controlled trials (RCTs) to determine […]
Abiomed slips 13% on lower forecast
Shares in Abiomed (NSDQ:ABMD) fell nearly 13% this morning after the company issued revenue guidance that missed Wall Street expectations. The Danvers, Mass.-based company said in an SEC filing that it expects sales of $221.6 million for the third quarter of its fiscal 2020 year, which ended Dec. 31, 2019. While that figure is 10% […]
- 1
- 2
- 3
- …
- 26
- Next Page »
